Video

Deprescribing Advice at Pri-Med West

Author(s):

Many patients, particularly older ones, are taking unnecessary medications.

It is sometimes important to take a step back from a patient’s medication program and decide whether something is necessary or unnecessary.

And for seniors that might be crucial.

In a presentation during Pri-Med West 2022 in Anaheim, Lee A. Lindquist, MD, MPH, Chief of the Division of Geriatrics at Northwestern University Feinberg School of Medicine, spoke about the need to deprescribe when possible, for the senior population.

However, for this to occur correctly there needs to be good communication between the different doctors and specialists.

In an interview with HCPLive®, Lindquist explained her Pri-Med presentation and how a deprescription initiative could work and be beneficial to seniors, particularly as the population is aging.

“So many of our seniors have too many medicines that are not relevant to what they need right now,” Lindquist said.

One of the reasons for the unnecessary medicines is that many people are prescribed medications in their 40s and 50s and continue to take them throughout life, even when they are not entirely necessary.

And the best times to take a look at the treatment schedule and possibly reduce medication is either after a wellness visit or a hospitalization.

Related Videos
Marcelo Kugelmas, MD | Credit: South Denver Gastroenterology
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.